Successor Wu Yifang, Chen Yuqing became the chairman of Fosun Pharmaceutical (02196)

The Zhitong Finance App learned that on April 29, Fosun Pharmaceutical (600196.SH; 02196) announced the results report for the first quarter of 2025. In the first quarter, Fosun Pharmaceutical achieved operating income of RMB 9.420 billion, net profit to mother of RMB 765 million, and cash flow from operating activities of RMB 1,056 million. During the reporting period, Fosun Pharmaceutical continued to promote innovative transformation and the development and implementation of innovative products. The self-developed slulizumab injection (EU trade name: Hetronifly) was approved in the European Union, and the world's first phosphorus absorption inhibitor, Vantille® (tenapanol hydrochloride tablets), was approved in China, and a number of ongoing research and innovation pipelines entered a critical clinical/approval stage. Furthermore, Fosun Pharmaceutical continues to strengthen global licensing cooperation and actively implement the internationalization strategy. In February 2025, the holding subsidiary Fuhong Hanlin granted Dr. Reddy's exclusive commercial rights for the two dosage forms of the daretuuman biosimilar drug HLX15 developed independently in the US and 42 European countries and regions to accelerate the entry of self-developed products into the European and American markets. Based on confidence in its own sustainable development and recognition of its value, Fosun Pharmaceutical launched and implemented a new round of A share and H share repurchases in the first quarter of 2025 to boost investor confidence and protect investors' interests.

On the same day, Fosun Pharmaceutical announced adjustments to the division of labor in the board of directors. After this adjustment, Wu Yifang will no longer serve as the executive director and chairman of Fosun Pharmaceuticals, and will be the executive president of Fosun Pharmaceuticals; Wang Kexin will no longer be the co-chairman of Fosun Pharmaceuticals, will continue to be the executive director of Fosun Pharmaceuticals, and will also serve as the executive president of Fosun International; Chen Yuqing is the chairman and executive director of Fosun Pharmaceuticals; and CEO Wen Deyong is the vice chairman and executive director of Fosun Pharmaceuticals. In the future, Chen Yuqing will be fully responsible for Fosun Pharmaceuticals' strategy and important tasks such as organizational development, team training, and talent reserve in line with strategic goals, leading the management team to achieve steady business growth and further consolidate the foundation for industrial development.

Chen Yuqing, Executive Director and Chairman of Fosun Pharmaceutical, said, “Every step of Fosun Pharmaceutical's growth brings together the wisdom and responsibility of the previous board of directors and management. We would like to especially thank Wu Yifang as Chairman and Wang Kexin as Co-Chairman for their efforts and dedication in leading the management team, further laying a solid foundation for Fosun Pharmaceutical's R&D innovation, international layout and commercialization capabilities. In the future, the board of directors of the company will continue to deepen innovation and internationalization strategies, lead the company to continue to focus on innovation, transformation and global layout, and accelerate the global development of innovative drugs and high-value devices. At the same time, seize the opportunity to accelerate the high-quality development of the medical and health service business, provide more high-quality medical products and services to patients, continuously improve business performance, and create long-term value for all stakeholders such as shareholders, employees, and partners.”

Since its establishment more than 30 years ago, Fosun Pharmaceutical has become a global medical and health industry group rooted in China and driven by innovation, and is committed to becoming the world's leading integrator of medical innovation. Fosun Pharmaceuticals is actively implementing the “4IN” (innovative innovation, internationalization, intelligent intelligentization, integration) strategy, and its core business has covered overseas markets such as the US, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharmaceutical has formed an open and global drug innovation research and development system, focusing on core treatment fields such as tumors (solid tumors, hematomas), immune inflammation, etc., focusing on strengthening antibody/ADC, cell therapy, and small molecule core technology platforms, and laying out cutting-edge technologies such as nuclear drugs, RNA, gene therapy, and AI drug development through cooperation with industry funds to continuously promote innovative transformation and the development and implementation of innovative products to solve unmet clinical needs.